Captrust Financial Advisors Biomarin Pharmaceutical Inc Transaction History

Captrust Financial Advisors

$33 Billion
Q3 2024

A detailed history of Captrust Financial Advisors transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Captrust Financial Advisors holds 10,900 shares of BMRN stock, worth $700,434. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,900

Previous 8,130 34.07%

Holding current value

$700,434

Previous $669,000 14.5%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$69.02 - $93.84 $191,185 - $259,936	2,770 Added 34.07%	10,900 $766,000
Q2 2024 Aug 14, 2024	BUY	$74.43 - $92.22 $169,551 - $210,077	2,278 Added 38.93%	8,130 $669,000
Q1 2024 May 15, 2024	SELL	$83.81 - $99.0 $123,619 - $146,025	-1,475 Reduced 20.13%	5,852 $511,000
Q4 2023 Feb 14, 2024	SELL	$76.22 - $98.51 $23,094 - $29,848	-303 Reduced 3.97%	7,327 $706,000
Q3 2023 Nov 14, 2023	BUY	$85.07 - $94.48 $166,141 - $184,519	1,953 Added 34.4%	7,630 $675,000
Q2 2023 Aug 14, 2023	BUY	$86.68 - $100.3 $77,665 - $89,868	896 Added 18.74%	5,677 $492,000
Q1 2023 May 15, 2023	BUY	$87.74 - $117.27 $124,590 - $166,523	1,420 Added 42.25%	4,781 $464,000
Q4 2022 Feb 15, 2023	BUY	$80.93 - $108.63 $19,018 - $25,528	235 Added 7.52%	3,361 $347,000
Q3 2022 Nov 16, 2022	BUY	$82.16 - $96.94 $1,807 - $2,132	22 Added 0.71%	3,126 $265,000
Q2 2022 Aug 23, 2022	SELL	$71.48 - $86.85 $1,358 - $1,650	-19 Reduced 0.61%	3,104 $257,000
Q2 2022 Aug 16, 2022	SELL	$71.48 - $86.85 $10,793 - $13,114	-151 Reduced 4.61%	3,123 $259,000
Q1 2022 May 16, 2022	SELL	$74.28 - $92.69 $34,317 - $42,822	-462 Reduced 12.37%	3,274 $252,000
Q4 2021 Feb 14, 2022	BUY	$71.72 - $91.47 $18,862 - $24,056	263 Added 7.57%	3,736 $330,000
Q3 2021 Nov 16, 2021	SELL	$74.77 - $85.47 $15,626 - $17,863	-209 Reduced 5.68%	3,473 $268,000
Q2 2021 Aug 16, 2021	BUY	$75.51 - $84.79 $22,653 - $25,437	300 Added 8.87%	3,682 $307,000
Q1 2021 May 17, 2021	BUY	$74.73 - $90.69 $5,455 - $6,620	73 Added 2.21%	3,382 $255,000
Q4 2020 Feb 16, 2021	SELL	$72.61 - $90.2 $30,568 - $37,974	-421 Reduced 11.29%	3,309 $290,000
Q3 2020 Nov 17, 2020	SELL	$71.87 - $131.03 $40,750 - $74,294	-567 Reduced 13.2%	3,730 $283,000
Q2 2020 Aug 14, 2020	SELL	$79.55 - $124.22 $16,466 - $25,713	-207 Reduced 4.6%	4,297 $541,000
Q1 2020 May 15, 2020	BUY	$71.37 - $96.85 $16,843 - $22,856	236 Added 5.53%	4,504 $376,000
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $82,458 - $110,812	1,283 Added 42.98%	4,268 $359,000
Q2 2019 Aug 13, 2019	SELL	$80.35 - $93.9 $17,757 - $20,751	-221 Reduced 6.89%	2,985 $256,000
Q1 2019 May 15, 2019	SELL	$84.2 - $98.62 $25,428 - $29,783	-302 Reduced 8.61%	3,206 $285,000
Q4 2018 Feb 13, 2019	BUY	$80.14 - $106.07 $19,874 - $26,305	248 Added 7.61%	3,508 $299,000
Q3 2018 Nov 15, 2018	BUY	$93.92 - $105.72 $306,179 - $344,647	3,260 New	3,260 $316,000

Others Institutions Holding BMRN

# of Institutions

636

Shares Held

178M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.9B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.

Account

Captrust Financial Advisors Biomarin Pharmaceutical Inc Transaction History